

quetiapine (Seroquel)

(No. 104/04)

AstraZeneca

Summary of Recommendation

12 July 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE: Following a full submission:

Quetiapine (Seroquel) is accepted for use within NHS Scotland for the treatment of manic episodes associated with bipolar disorder as monotherapy or as adjunct therapy to mood stabilisers.

Active comparators were included in the monotherapy trials but the studies were not designed to show differences between active comparator and quetiapine. It has not been compared to other atypical antipsychotics in this indication.

Economic data suggest that quetiapine (Seroquel) is at least cost neutral, compared to other licensed approaches using atypical antipsychotics in this indication, either as adjunctive therapy or monotherapy.

Professor David Webb
Deputy Chairman